As of November 6, 2026, Bicycle Therapeutics plc is a publicly traded company (Nasdaq: BCYC); its largest reported holder is Armistice Capital, with 6.72% on Schedule 13G/A of August 14, 2026, then Long Focus Capital Management, LLC (6.6%) (Schedule 13G/A, August 14, 2026).
Is this your company?
About to sign with, pay or invest in Bicycle Therapeutics plc? See the free Snapshot first.
Free to see. No signup.
Is Bicycle Therapeutics plc a real, registered company?
- Bicycle Therapeutics plc files with the SEC under CIK 1761612 (its SEC filings).
- Its shares are listed under the ticker BCYC on Nasdaq (SEC company record).
- Incorporated in X0; business address in Cambridge, X0, as its SEC filings state.
- Court and bankruptcy records: see Before you sign or pay below.
Before you sign or pay
- Court and bankruptcy: No federal court case or bankruptcy filing found under BICYCLE THERAPEUTICS PLC in our court records and SEC 8-K records (as of 2026-11-06).
- Leadership changes: the latest reported is Charles Swanton, Director (Form 8-K filed 2026-08-20). Check you are dealing with the people now in charge.
- Ownership: 5%+ holders are reported on Schedule 13D or 13G; the latest names Armistice Capital (filed 2026-08-14).
Who are Bicycle Therapeutics plc's owners and officers?
Bicycle Therapeutics plc: business address in Cambridge, X0; industry Pharmaceutical Preparations (Form D, 2026-08-20).
Officers and directors, each with the role and the filing that names them:
- : Executive Officer, Director (Form D, 2024-06-12)
- : Executive Officer (Form D, 2024-06-12)
- : Director (Form D, 2024-06-12)
- : Director (Form D, 2024-06-12)
- : Director (Form D, 2024-06-12)
- : Director (Form D, 2024-06-12)
- : Director (Form D, 2024-06-12)
- : Director (Form D, 2024-06-12)
- : Director (Form D, 2024-06-12)
- : Executive Officer (Form D, 2024-06-12)
- : Executive Officer (Form D, 2024-06-12)
- : Executive Officer (Form D, 2024-06-12)
| Report | Holder | Share |
|---|---|---|
| Schedule 13G/A, 2026-08-14 | Armistice Capital, LLC | 6.72% |
| Schedule 13G, 2026-05-15 | Long Focus Capital Management, LLC | 6.6% |
| Schedule 13G/A, 2026-05-15 | Armistice Capital, LLC | 6.75% |
| Schedule 13G/A, 2026-05-04 | Raymond Debbane | 3.1% |
| Schedule 13G/A, 2026-03-04 | Westfield Capital Management Company, L.P. | 0% |
| Schedule 13G/A, 2026-03-03 | Westfield Capital Management Company, L.P. | 0% |
| Schedule 13G/A, 2026-03-03 | Westfield Capital Management Company, L.P. | 0% |
| Schedule 13G, 2026-03-03 | Raymond Debbane | 6.3% |
| Schedule 13G, 2026-02-18 | Armistice Capital, LLC | 6.48% |
| Schedule 13G/A, 2026-02-11 | Westfield Capital Management Company, L.P. | 6.04% |
| Schedule 13G/A, 2025-08-14 | Deep Track Capital, LP | 2.42% |
| Schedule 13G/A, 2025-08-14 | Point72 Asset Management, L.P. | 3.9% |
Questions about who owns Bicycle Therapeutics plc
Who owns Bicycle Therapeutics plc?
On this page, 2 holders' latest ownership filings report 5% or more of Bicycle Therapeutics plc: Armistice Capital, LLC (6.72%, Schedule 13G/A, filed 2026-08-14) and Long Focus Capital Management, LLC (6.6%, Schedule 13G, filed 2026-05-15).
Who are the largest shareholders of Bicycle Therapeutics plc?
By the share each holder's latest filing reports, the largest holders of Bicycle Therapeutics plc on this page are Armistice Capital, LLC (6.72%) and Long Focus Capital Management, LLC (6.6%).
When did Armistice Capital, LLC buy into Bicycle Therapeutics plc?
The filings give report dates, not purchase dates. The earliest filing from Armistice Capital, LLC on this page is the Schedule 13G, filed 2026-02-18, reporting 6.48%; its latest, Schedule 13G/A filed 2026-08-14, reports 6.72%.
Is this an audit or a full list?
Neither. The ownership list on this page covers only Schedule 13D and 13G filings, which holders make once they own 5% or more of a class of shares (an amendment can report a stake that has since fallen below 5%); 12 such filings are shown here. It is not an audit and not a full cap table: holders who never reached 5% are not listed, and a stake can change after its latest filing.
Want the whole picture on Bicycle Therapeutics plc?
Example from a real report (our sample on Target): “Target eliminated approximately 1,800 corporate positions, with around 1,000 employees receiving layoff notices and the remainder accounted for by eliminating open roles.” Source: NBC News
A Full Report on Bicycle Therapeutics plc: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Bicycle Therapeutics plc covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
16 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
| Filed | Person | Role | Change | Effective |
|---|---|---|---|---|
| Form 8-K, 2026-08-20 | Charles Swanton | Director | departed |
Which insiders own Bicycle Therapeutics plc shares?
Directors, officers and holders of 10% or more report their shares on Forms 3, 4 and 5. Each line is the latest such report, largest holding first.
- , a director and 10% owner: 10,018,674 shares (33.3% of shares outstanding), held indirectly (the form names the holder only in its footnotes), on a joint filing (Form 4, 2026-01-06).
- , a director and 10% owner: 10,018,674 shares (33.3% of shares outstanding), held indirectly (the form names the holder only in its footnotes), on a joint filing (Form 4, 2026-01-06).
- Baker Bros. Advisors LP, a director and 10% owner: 10,018,674 shares (33.3% of shares outstanding), held indirectly (the form names the holder only in its footnotes), on a joint filing (Form 4, 2026-01-06).
- 667, L.P., a director and 10% owner: 10,018,674 shares (33.3% of shares outstanding), held indirectly (the form names the holder only in its footnotes), on a joint filing (Form 4, 2026-01-06).
- Baker Bros. Advisors (GP) LLC, a director and 10% owner: 10,018,674 shares (33.3% of shares outstanding), held indirectly (the form names the holder only in its footnotes), on a joint filing (Form 4, 2026-01-06).
Shares outstanding: 30,043,486 as of 2023-05-01, from the company's latest SEC cover page.
How much has Bicycle Therapeutics plc raised?
| Filed | Sold | Offered |
|---|---|---|
| Form D, 2024-06-12 | $555.50M | $555.50M |
Keep reading
More on Bicycle Therapeutics plc and the records around it.
Bicycle Therapeutics plc elsewhere on the record
- 5%+ stake filings Aug 2026
Companies that share a holder
- Westfield Capital Management Company, L.P. also filed stake reports on 2 other companies: IMAX CORP (Jun 2026), Ascendis Pharma A/S (Feb 2026)
- LONG FOCUS CAPITAL MANAGEMENT, LLC also filed stake reports on 8 other companies: AURA BIOSCIENCES, INC. (Aug 2026), STANDARD BIOTOOLS INC. (Aug 2026), ONITY GROUP INC. (May 2026)
- Invus Public Equities, L.P. also filed stake reports on 24 other companies: City Therapeutics, Inc. (Oct 2026), Yarrow Bioscience, Inc. (Sep 2026), Abivax S.A. (Aug 2026)
Related pages
Filings, cases and notices link to their records. A not-found line names the records searched; it is not proof of absence.
Not for employment, credit, insurance or tenancy decisions.
Cite this page
https://mentionfox.com/who-owns/bicycle-therapeutics